By Fineline Cube 
Suzhou HemaCell Therapeutics (HemaCell), a pioneering cell therapy developer focused on platelet regeneration, announced the completion of its second Series B closing, securing RMB 100 million ($14.78 million) and bringing total Series B funding to nearly RMB 300 million ($44.36 million).
Financing Details & Investor Consortium
| Parameter | Detail |
|---|---|
| Company | Suzhou HemaCell Therapeutics (HemaCell) |
| Financing Round | Series B (Second Closing) |
| Total Series B Raised | RMB 300 million ($44.36 million) |
| Second Closing Amount | RMB 100 million ($14.78 million) |
| New Investors | Shenzhen Capital Group (SCGC), Hebei Industrial Investment Group |
| Existing Investors | CDH Investment, Weidu Capital (additional participation) |
| Next Milestone | Pre-IPO round planned for late 2026 |
Product Pipeline & Development Strategy
Flagship Program: Megakaryocyte Injection
- Innovation: World’s first megakaryocyte injection for platelet regeneration
- Clinical Focus: Multiple indications addressing platelet deficiency disorders
- Development Stage: Advancing through clinical trials with Series B funding
- Therapeutic Rationale: Direct cellular approach to generate functional platelets in vivo
Pipeline Expansion
- Platelet Injection Programs: Developing next-generation platelet-derived therapeutics
- Aging-Related Indications: Novel applications leveraging platelet biology for age-related conditions
- Manufacturing Infrastructure: Capital allocation for GMP-compliant production facilities
Market Opportunity & Unmet Medical Need
| Aspect | Analysis |
|---|---|
| Global Blood Shortage Crisis | Chronic platelet supply shortages affect 85+ countries; shelf-life limitations (5-7 days) exacerbate supply chain challenges |
| Transfusion-Associated Risks | 1-3% of transfusions result in adverse reactions; blood-borne disease transmission remains concern despite screening |
| Cell Therapy Advantage | On-demand platelet production could eliminate supply constraints and reduce transfusion complications |
| Aging Population Impact | Growing elderly population increases demand for platelet support during cancer therapy and surgical procedures |
| Market Size | Global platelet market estimated at $8.2 billion annually; cell-based alternatives represent disruptive opportunity |
Strategic Roadmap & Capital Allocation
- Clinical Development: Primary allocation to advance multiple clinical trials for megakaryocyte injection
- Manufacturing Scale-Up: Support construction of dedicated manufacturing bases for commercial-scale production
- Pipeline Diversification: Develop novel platelet-derived drugs targeting aging-related therapeutic areas
- Pre-IPO Preparation: Planned late-2026 Pre-IPO round to fund commercial infrastructure and expand production capacity
- Regulatory Strategy: Leverage Chinese regulatory advantages while preparing for international development pathways
The substantial Series B backing from both new strategic investors and existing shareholders validates HemaCell’s innovative approach to addressing one of healthcare’s most persistent supply chain challenges—reliable access to life-saving platelets.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financing activities, clinical development plans, and commercial expectations. Actual results may differ due to risks including regulatory outcomes, clinical trial results, and market conditions.-Fineline Info & Tech